Видео ютуба по тегу Sarah Cannon Research Institute

Evolving cancer treatment conversations with your doctor
Evolving cancer treatment conversations with your doctor
Allogeneic CAR-T Cell Therapy for Multiple Myeloma Jesus Berdeja, MD, Sarah Cannon
Allogeneic CAR-T Cell Therapy for Multiple Myeloma Jesus Berdeja, MD, Sarah Cannon
An update on research into JNJ-90014496 for DLBCL
An update on research into JNJ-90014496 for DLBCL
First promising results of exa-cel in pediatric patients with TDT or SCD and recurrent severe VOCs
First promising results of exa-cel in pediatric patients with TDT or SCD and recurrent severe VOCs
HR+ рак молочной железы: применение инаволисиба в качестве терапии первой линии и новые адъювантн...
HR+ рак молочной железы: применение инаволисиба в качестве терапии первой линии и новые адъювантн...
Анализ «прорывного года» в области лечения рака груди.
Анализ «прорывного года» в области лечения рака груди.
Outpatient use of liso-cel in patients with R/R LBCL: real-world data from the CIBMTR registry
Outpatient use of liso-cel in patients with R/R LBCL: real-world data from the CIBMTR registry
Лечение рецидива после адъювантной терапии ингибиторами CDK4/6 при ER-позитивном раке молочной же...
Лечение рецидива после адъювантной терапии ингибиторами CDK4/6 при ER-позитивном раке молочной же...
Последние достижения в лечении лимфомы и ХЛЛ: мнение доктора Криша Пателя.
Последние достижения в лечении лимфомы и ХЛЛ: мнение доктора Криша Пателя.
Доктор Ханс Ли о революционных исследованиях миеломы, представленных на конференции ASH 2025.
Доктор Ханс Ли о революционных исследованиях миеломы, представленных на конференции ASH 2025.
HCA1225 V4
HCA1225 V4
HER2CLIMB-05: the role of tucatinib in HER2-positive metastatic breast cancer
HER2CLIMB-05: the role of tucatinib in HER2-positive metastatic breast cancer
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
HER2CLIMB-05: tucatinib improves progression-free survival in HER2+ metastatic breast cancer
HER2CLIMB-05: tucatinib improves progression-free survival in HER2+ metastatic breast cancer
Bispecific antibodies in myeloma: top trial updates from ASH 2025
Bispecific antibodies in myeloma: top trial updates from ASH 2025
CAR T-Cell Therapy Insights from the Field
CAR T-Cell Therapy Insights from the Field
Lung Cancer Awareness: Dr. Melissa Johnson on Early Detection & Breakthrough Treatment|NewsChannel 5
Lung Cancer Awareness: Dr. Melissa Johnson on Early Detection & Breakthrough Treatment|NewsChannel 5
Blood & Marrow Transplant 101 - Sarah Cannon Cancer Network (Spanish)
Blood & Marrow Transplant 101 - Sarah Cannon Cancer Network (Spanish)